Depen: Medgend

Search instead for depends

Depen FDA Approved Drugs

BUNAVAIL [Buprenorphine Hydrochloride^{C₂₉H₄₁NO₄ClH} : Naloxone Hydrochloride^{C₁₉H₂₁NO₄ClH}]

eq 2.1mg base : eq 0.3mg base (buccal film)

eq 4.2mg base : eq 0.7mg base (buccal film)

eq 6.3mg base : eq 1mg base (buccal film)

Bdsi^{Jun 6, 2014}

Maintenance treatment of opioid dependence.
Treatment of opioid dependence.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

CUPRIMINE [Penicillamine^{C₅H₁₁NO₂S}]

250mg (oral capsule)

Aton^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

DEPEN [Penicillamine^{C₅H₁₁NO₂S}]

250mg (oral tablet)

Mylan Speciality Lp^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

GATTEX KIT [Teduglutide Recombinant]

5mg/vial (subcutaneous powder)

Nps Pharms Inc^{Dec 21, 2012}

Treatment of adult patients with short bowel syndrome who are dependent on parenteral support.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

PROBUPHINE [Buprenorphine Hydrochloride^{C₂₉H₄₁NO₄ClH}]

eq 80mg base/implant (implantation implant)

Braeburn Pharms Inc^{May 26, 2016}

For opioid dependence.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

REVLIMID [Lenalidomide^{C₁₃H₁₃N₃O₃}]

10mg (oral capsule)

15mg (oral capsule)

2.5mg (oral capsule)

20mg (oral capsule)

25mg (oral capsule)

Celgene^{Dec 27, 2005}

Treatment of male patient having a disease or condition responsive to a teratogenic drug.
Use of revlimid (lenalidomide) for the treatment of mantle cell lymphoma (mcl).
Use of revlimid (lenalidomide) for the treatment of multiple myeloma and transfusion-dependent anemia in myelodysplastic syndromes (mds).
Use of revlimid (lenalidomide) for the treatment of multiple myeloma.
Use of revlimid (lenalidomide) for the treatment of transfusion-dependent anemia in myelodysplastic syndromes (mds).
Use of revlimid (lenalidomide) to inhibit the secretion of pro-inflammatory cytokines, including tumor necrosis factor alpha.
Use of revlimid (lenalidomide) while preventing the exposure of a fetus or other contraindicated individual to revlimid (lenalidomide).

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

SUBOXONE [Buprenorphine Hydrochloride^{C₂₉H₄₁NO₄ClH} : Naloxone Hydrochloride^{C₁₉H₂₁NO₄ClH}]

eq 12mg base : eq 3mg base (buccal, sublingual film)

eq 2mg base : eq 0.5mg base (buccal, sublingual film)

eq 4mg base : eq 1mg base (buccal, sublingual film)

eq 8mg base : eq 2mg base (buccal, sublingual film)

Indivior Inc^{Aug 10, 2012}

This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence.
Treatment of opioid dependence/sublingual or buccal application.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

VIVITROL [Naltrexone^{C₂₀H₂₃NO₄}]

380mg/vial (intramuscular for suspension, extended release)

Alkermes^{Apr 13, 2006}

Prevention of relapse to opioid dependence, following opioid detoxification.
Treatment of alcohol dependence.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.